538 related articles for article (PubMed ID: 11093076)
21. Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach.
Ukawa H; Yamakuni H; Kato S; Takeuchi K
Dig Dis Sci; 1998 Sep; 43(9):2003-11. PubMed ID: 9753266
[TBL] [Abstract][Full Text] [Related]
22. Cyclo-oxygenase isozymes in mucosal ulcergenic and functional responses following barrier disruption in rat stomachs.
Hirata T; Ukawa H; Yamakuni H; Kato S; Takeuchi K
Br J Pharmacol; 1997 Oct; 122(3):447-54. PubMed ID: 9351500
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo pharmacological evidence of selective cyclooxygenase-2 inhibition by nimesulide: an overview.
Famaey JP
Inflamm Res; 1997 Nov; 46(11):437-46. PubMed ID: 9427063
[TBL] [Abstract][Full Text] [Related]
24. Gastroprotective and ulcer healing effects of nitric oxide-releasing non-steroidal anti-inflammatory drugs.
Brzozowski T; Konturek PC; Konturek SJ; Sliwowski Z; Drozdowicz D; Kwiecień S; Pajdo R; Ptak A; Pawlik M; Hahn E
Dig Liver Dis; 2000 Oct; 32(7):583-94. PubMed ID: 11142556
[TBL] [Abstract][Full Text] [Related]
25. Characterization of the induction of nitric oxide synthase and cyclo-oxygenase in rat aorta in organ culture.
Bishop-Bailey D; Larkin SW; Warner TD; Chen G; Mitchell JA
Br J Pharmacol; 1997 May; 121(1):125-33. PubMed ID: 9146896
[TBL] [Abstract][Full Text] [Related]
26. Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects.
Panara MR; Renda G; Sciulli MG; Santini G; Di Giamberardino M; Rotondo MT; Tacconelli S; Seta F; Patrono C; Patrignani P
J Pharmacol Exp Ther; 1999 Jul; 290(1):276-80. PubMed ID: 10381787
[TBL] [Abstract][Full Text] [Related]
27. Natriuretic response to increased pressure is preserved with COX-2 inhibitors.
Gross JM; Dwyer JE; Knox FG
Hypertension; 1999 Nov; 34(5):1163-7. PubMed ID: 10567199
[TBL] [Abstract][Full Text] [Related]
28. Wound collagen deposition in rats: effects of an NO-NSAID and a selective COX-2 inhibitor.
Muscará MN; McKnight W; Asfaha S; Wallace JL
Br J Pharmacol; 2000 Feb; 129(4):681-6. PubMed ID: 10683192
[TBL] [Abstract][Full Text] [Related]
29. Meloxicam inhibits the growth of colorectal cancer cells.
Goldman AP; Williams CS; Sheng H; Lamps LW; Williams VP; Pairet M; Morrow JD; DuBois RN
Carcinogenesis; 1998 Dec; 19(12):2195-9. PubMed ID: 9886578
[TBL] [Abstract][Full Text] [Related]
30. Differential inhibition by nimesulide of the early and late phases of intravenous- and intracerebroventricular-LPS-induced fever in guinea pigs.
Steiner AA; Li S; Llanos-Q J; Blatteis CM
Neuroimmunomodulation; 2001; 9(5):263-75. PubMed ID: 11964521
[TBL] [Abstract][Full Text] [Related]
31. Meloxicam: influence on arachidonic acid metabolism. Part 1. In vitro findings.
Engelhardt G; Bögel R; Schnitzer C; Utzmann R
Biochem Pharmacol; 1996 Jan; 51(1):21-8. PubMed ID: 8534264
[TBL] [Abstract][Full Text] [Related]
32. Effect of the selective COX-2 inhibitors, celecoxib and rofecoxib in rat acute models of inflammation.
Pinheiro RM; Calixto JB
Inflamm Res; 2002 Dec; 51(12):603-10. PubMed ID: 12558194
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo assay to determine the cyclooxygenase selectivity of non-steroidal anti-inflammatory drugs.
Giuliano F; Warner TD
Br J Pharmacol; 1999 Apr; 126(8):1824-30. PubMed ID: 10372826
[TBL] [Abstract][Full Text] [Related]
34. Induction of cyclooxygenase-2 in rat gastric mucosa by rebamipide, a mucoprotective agent.
Sun WH; Tsuji S; Tsujii M; Gunawan ES; Kawai N; Kimura A; Kakiuchi Y; Yasumaru M; Iijima H; Okuda Y; Sasaki Y; Hori M; Kawano S
J Pharmacol Exp Ther; 2000 Nov; 295(2):447-52. PubMed ID: 11046075
[TBL] [Abstract][Full Text] [Related]
35. Effect of selective vs. non-selective cyclo-oxygenase inhibitors on fetal membrane prostaglandin synthesis.
Sawdy R; Pan H; Sullivan M; Bennett P
J Obstet Gynaecol; 2003 May; 23(3):239-43. PubMed ID: 12850850
[TBL] [Abstract][Full Text] [Related]
36. Bacterial lipopolysaccharide protects gastric mucosa against acute injury in rats by activation of genes for cyclooxygenases and endogenous prostaglandins.
Konturek PC; Brzozowski T; Konturek SJ; Taut A; Kwiecien S; Pajdo R; Sliwowski Z; Hahn EG
Digestion; 1998; 59(4):284-97. PubMed ID: 9693198
[TBL] [Abstract][Full Text] [Related]
37. Central antinociceptive effects of meloxicam on rat spinal cord in vitro.
Lopez-Garcia JA; Laird JM
Neuroreport; 1998 Mar; 9(4):647-51. PubMed ID: 9559932
[TBL] [Abstract][Full Text] [Related]
38. Preferential inhibition of cyclooxygenase-2 by meloxicam in human rheumatoid synoviocytes.
Tsubouchi Y; Sano H; Yamada R; Hashiramoto A; Kohno M; Kusaka Y; Kondo M
Eur J Pharmacol; 2000 May; 395(3):255-63. PubMed ID: 10812057
[TBL] [Abstract][Full Text] [Related]
39. Cyclooxygenase-1 mediates the final stage of morphine-induced delayed cardioprotection in concert with cyclooxygenase-2.
Jiang X; Shi E; Nakajima Y; Sato S; Ohno K; Yue H
J Am Coll Cardiol; 2005 May; 45(10):1707-15. PubMed ID: 15893191
[TBL] [Abstract][Full Text] [Related]
40. [The effect of cyclooxygenase-2 inhibitor on acute lung injury].
Wang J; Mao B; Chen Z
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Jun; 22(6):351-3. PubMed ID: 11775825
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]